Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression
Primary Purpose
Symptomatic Irreversible Pulpitis
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Prednisolone 30 mg
Diclofenac Potassium 50mg Tab
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Symptomatic Irreversible Pulpitis focused on measuring prednisolone, diclofenac potassium, interleukin-8
Eligibility Criteria
Inclusion Criteria:
- Age between 18-50 years.
- Males and females.
- American Society of Anesthesiologists class 1 or 2.
Mandibular premolar teeth with:
- Endodontic pulpal diagnosis of symptomatic irreversible pulpitis
- Normal/slight widening in the periodontal membrane space (PMS).
- Patients who had not taken any anti-inflammatory drugs the day of the root canal procedure unless they belong to one of the intervention groups.
- Patients who accept to participate in the trial, understand the VAS, and can sign the informed consent
Exclusion Criteria:
- Cases with acute peri-apical conditions (acute apical periodontitis/ acute apical abscess), pulpal necrosis, previously initiated therapy, or previously treated.
- Teeth other than single-rooted teeth.
- Radiographic evidence of external or internal root resorption vertical root fracture, perforation, or calcification.
- Immature teeth.
- Unrestorable teeth or teeth with severe periodontal disease.
- Patients with a known allergy, sensitivity, or history of other adverse reactions to the medications administered.
- Patients with a history of active peptic ulcer within the preceding 12 months, bleeding problems, anticoagulant use within the last month, or kidney disease.
- Patients who took analgesics/ anti-inflammatory drugs (steroidal or non-steroidal) the day of endodontic treatment.
- Pregnant or nursing females.
- Patients who are unable to provide informed consent
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Prednisolone premedication
Diclofenac potassium premedication
Placebo
Arm Description
Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
Placebo tablet 1 hour before starting endodontic treatment.
Outcomes
Primary Outcome Measures
Change in the intensity of post-endodontic pain
Pain intensity will be evaluated using visual analogue scale
Secondary Outcome Measures
Quantification of pulpal IL-8
Il-8 analasys will be done via enzyme-linked immunosorbent assay (ELISA)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04608981
Brief Title
Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression
Official Title
Effect of Diclofenac Potassium Versus Prednisolone as a Premedication on Post-endodontic Pain and Pulpal Interleukin (IL)-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 2021 (Anticipated)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
February 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To assess the effect of using diclofenac potassium versus prednisolone as a pre-medication compared to placebo on:
Intensity of post-endodontic pain in patients with symptomatic irreversible pulpitis.
Pulpal IL-8 expression.
Incidence of post-endodontic pain in patients with symptomatic irreversible pulpitis.
Detailed Description
After confirming the diagnosis and making sure that the patient conforms to all eligibility criteria, the principal investigator will enroll the patient in the study.
Patients will be asked to rate their pre-operative pain intensity (ie, before the commencement of any treatment [baseline score]; on the visual analogue scale "VAS"
Enrolled patients will be randomly assigned into one of three groups:
Intervention Group 1 (Diclofenac Potassium): single, oral dose of 50 mg diclofenac potassium pre-medication (Cataflam; NOVARTIS Pharma, Basel, Switzerland) one hour before starting endodontic treatment.
Intervention Group 2 (Prednisolone): single, oral dose of 30 mg prednisolone (one and a half tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France) 30 min before starting endodontic treatment.
Control Group (Placebo): The patients assigned to this group will be given a placebo tablet (Starch, Bridgewater, NJ) one hour before starting endodontic treatment.
- Root canal therapy in all groups will be completed by the principal investigator in a single visit as follows:
Anesthetizing the tooth using inferior alveolar nerve block technique by local anesthesia of 1.8 ml of 2% Mepivacaine HCl with 1:100,000 epinephrine.
After anesthesia is achieved and verified with Endo-Ice, the patient's tooth is isolated with a rubber dam, caries is excavated, and the pulp is exposed with a sterile round bur.
Preparation of access cavity using a sterile round carbide bur and an Endo-Z bur
Sample Collection:
Blood from the exposed surface of the pulp will be collected with 2 sterile cotton pellets.
The pellets will be held at the exposure site for 45-60 seconds to allow absorption of the blood from the pulpal tissue.
The pellets will be placed in 1.0 mL saline in heparin-coated tubes.
Samples will be placed on ice and stored/refrigerated immediately at -20 degrees celsius until they are ready to be tested.
After the pulpal blood sample is collected, patency of the root canals will be confirmed using stainless steel hand K-files sizes #10 and #15.
Working length will be determined using an electronic apex locator then confirmed radiographically to be 1 mm shorter than radiographic apex.
Mechanical preparation will be completed in a crown down technique with ProTaper Next10 rotary files set on an endodontic motor adjusted at a speed of 300 rpm and torque of 200 gcm. In-and-out motions will be applied with stroke lengths not exceeding 3mm in the cervical, middle, and apical thirds until attaining the established WL.
The root canal will be thoroughly irrigated with 3 mL of 2.6% sodium hypochlorite using a plastic disposable syringe with a 30-gauge side-vented needle reaching 1mm short of the working length between every subsequent instrument, whereas saline will be used as the final irrigant.
The canal will then be dried using sterile paper points. Master cone fit radiograph will be taken and then the root canal will be obturated at the same appointment with matching-size gutta percha points and resin-based sealer using cold lateral compaction technique.
Access cavity will be sealed with Coltosol F temporary filling material.
At the end of the session, each patient will be instructed to complete a pain diary, (VAS), at specific intervals; immediately after treatment completion; and 6, 12, 24, and 48 hours after the completion of treatment. The patient will be asked to mark the level of pain on this 10-cm line. The distance from the left end to the mark made by the patient, which will be measured by the operator with a ruler, is the pain intensity.
Patients will be contacted by their operator at each time-point to check on them and as a reminder. Then, information will be documented.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Symptomatic Irreversible Pulpitis
Keywords
prednisolone, diclofenac potassium, interleukin-8
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
In this proposed study, the participant, and the assessor will be blinded. The participants will be blinded to the study hypothesis as to which intervention is expected to be better.
The patients, who already do not know their treatment group, will assess the level of their post-endodontic pain.
The laboratory technician at the microbiological department will not know the treatment group of the patients.
The treatment groups will remain anonymous at the end of the study during assessment by the statistician.
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Prednisolone premedication
Arm Type
Experimental
Arm Description
Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
Arm Title
Diclofenac potassium premedication
Arm Type
Experimental
Arm Description
Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablet 1 hour before starting endodontic treatment.
Intervention Type
Drug
Intervention Name(s)
Prednisolone 30 mg
Other Intervention Name(s)
One and a half tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France
Intervention Description
Steroidal anti-inflammatory drug as a preoperative medication
Intervention Type
Drug
Intervention Name(s)
Diclofenac Potassium 50mg Tab
Other Intervention Name(s)
Cataflam; NOVARTIS Pharma, Basel, Switzerland
Intervention Description
Non-steroidal anti-inflammatory drug as a preoperative medication
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Starch
Primary Outcome Measure Information:
Title
Change in the intensity of post-endodontic pain
Description
Pain intensity will be evaluated using visual analogue scale
Time Frame
Immediately after treatment completion; and at 6, 12, 24, and 48 hours post-operatively
Secondary Outcome Measure Information:
Title
Quantification of pulpal IL-8
Description
Il-8 analasys will be done via enzyme-linked immunosorbent assay (ELISA)
Time Frame
During the procedure
Other Pre-specified Outcome Measures:
Title
Change in the incidence of post-endodontic pain
Description
Pain incidence will be evaluated using visual analogue scale
Time Frame
Immediately after treatment completion; and at 6, 12, 24, and 48 hours post-operatively
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age between 18-50 years.
Males and females.
American Society of Anesthesiologists class 1 or 2.
Mandibular premolar teeth with:
Endodontic pulpal diagnosis of symptomatic irreversible pulpitis
Normal/slight widening in the periodontal membrane space (PMS).
Patients who had not taken any anti-inflammatory drugs the day of the root canal procedure unless they belong to one of the intervention groups.
Patients who accept to participate in the trial, understand the VAS, and can sign the informed consent
Exclusion Criteria:
Cases with acute peri-apical conditions (acute apical periodontitis/ acute apical abscess), pulpal necrosis, previously initiated therapy, or previously treated.
Teeth other than single-rooted teeth.
Radiographic evidence of external or internal root resorption vertical root fracture, perforation, or calcification.
Immature teeth.
Unrestorable teeth or teeth with severe periodontal disease.
Patients with a known allergy, sensitivity, or history of other adverse reactions to the medications administered.
Patients with a history of active peptic ulcer within the preceding 12 months, bleeding problems, anticoagulant use within the last month, or kidney disease.
Patients who took analgesics/ anti-inflammatory drugs (steroidal or non-steroidal) the day of endodontic treatment.
Pregnant or nursing females.
Patients who are unable to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed A Soliman, MSc
Phone
+201006779533
Email
aasoliman89@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sara S Abouelenien, PhD
Phone
+201000703203
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed A Soliman, MSc
Organizational Affiliation
Cairo University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Khaled Ezzat, PhD
Organizational Affiliation
Cairo University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Sara S Abouelenien, PhD
Organizational Affiliation
Cairo University
Official's Role
Study Chair
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression
We'll reach out to this number within 24 hrs